Literature DB >> 16545016

Phenotypic drug resistance patterns in subtype A HIV-1 clones with nonnucleoside reverse transcriptase resistance mutations.

Susan H Eshleman1, Dana Jones, Justin Galovich, Ellen E Paxinos, Christos J Petropoulos, J Brooks Jackson, Neil Parkin.   

Abstract

We analyzed the nonnucleoside reverse transcriptase (RT) inhibitor (NNRTI) susceptibility of 29 subtype A HIV-1 clones isolated from 10 Ugandan women after single-dose nevirapine (NVP) administration. Six clones had no NNRTI resistance-associated mutations ("wild type"), eight had K103N, nine had Y181C, five had G190A, and one had Y181S. Three clones displayed unexpected phenotypic drug susceptibility/resistance based on their RT genotypes. One wild-type clone had reduced susceptibility to NVP, delavirdine (DLV), and efavirenz (EFV), one clone with K103N was susceptible to all three NNRTIs, and one clone with G190A had extreme hypersusceptibility to DLV. Three unusual HIV-1 RT amino acid substitutions may have contributed to the unexpected phenotypes of the clones: I31T, N136S, and N265D. These polymorphisms were rarely detected among 47,900 HIV-1 genotypes from clinical samples of predominantly United States origin. Further studies are needed to define the genetic correlates of antiretroviral drug resistance in nonsubtype B HIV-1.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16545016     DOI: 10.1089/aid.2006.22.289

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  8 in total

1.  Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda.

Authors:  Steven J Reynolds; Oliver Laeyendecker; Gertrude Nakigozi; Joel E Gallant; Wei Huang; Sarah E Hudelson; Thomas C Quinn; Kevin Newell; David Serwadda; Ronald H Gray; Maria J Wawer; Susan H Eshleman
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-26       Impact factor: 2.205

Review 2.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

3.  Molecular Epidemiology of HIV-1 Virus in Puerto Rico: Novel Cases of HIV-1 Subtype C, D, and CRF-24BG.

Authors:  Pablo López; Omayra De Jesús; Yasuhiro Yamamura; Nayra Rodríguez; Andrea Arias; Raphael Sánchez; Yadira Rodríguez; Vivian Tamayo-Agrait; Wilfredo Cuevas; Vanessa Rivera-Amill
Journal:  AIDS Res Hum Retroviruses       Date:  2018-05-23       Impact factor: 2.205

4.  Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus.

Authors:  Sara M O'Rourke; Becky Schweighardt; Pham Phung; Dora P A J Fonseca; Karianne Terry; Terri Wrin; Faruk Sinangil; Phillip W Berman
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

5.  Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies.

Authors:  Matthew S Lalonde; Ryan M Troyer; Aslam R Syed; Stanley Bulime; Korey Demers; Francis Bajunirwe; Eric J Arts
Journal:  J Clin Microbiol       Date:  2007-06-13       Impact factor: 5.948

Review 6.  Avoiding Drug Resistance in HIV Reverse Transcriptase.

Authors:  Maria E Cilento; Karen A Kirby; Stefan G Sarafianos
Journal:  Chem Rev       Date:  2021-01-28       Impact factor: 60.622

7.  Computational development of rubromycin-based lead compounds for HIV-1 reverse transcriptase inhibition.

Authors:  Carlos E P Bernardo; Pedro J Silva
Journal:  PeerJ       Date:  2014-07-10       Impact factor: 2.984

8.  Predominance of positive epistasis among drug resistance-associated mutations in HIV-1 protease.

Authors:  Tian-Hao Zhang; Lei Dai; John P Barton; Yushen Du; Yuxiang Tan; Wenwen Pang; Arup K Chakraborty; James O Lloyd-Smith; Ren Sun
Journal:  PLoS Genet       Date:  2020-10-21       Impact factor: 5.917

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.